Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3109-3116

  Stevens, Miguel ^a   Pannecouque, Christophe ^a   De Clercq, Erik ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GREEN FLUORESCENT PROTEIN; JPL 10; JPL 133; JPL 153; JPL 30; JPL 32; JPL 44; JPL 58; JPL 88; LAMIVUDINE; PHOTOPROTEIN; PYRIDINE 1 OXIDE; PYRIDINIUM DERIVATIVE; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL LINE; CELL SURVIVAL; CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, VIRAL; GREEN FLUORESCENT PROTEINS; HELA CELLS; HIV; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LUMINESCENT PROTEINS; MICROBIAL SENSITIVITY TESTS; PYRIDINIUM COMPOUNDS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0141925605     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3109-3116.2003     Document Type: Article

References (19)

1. Baba, M., D. Schols, R. Pauwels, H. Nakashima, and E. De Clercq. 1990. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy toward AIDS chemotherapy. J. Acquir. Immune Defic. Syndr. 3:493-499.
2. Baba, M. 1997. Cellular factors as alternative targets for inhibition of HIV-1. Antivir. Res. 33:141-152.
3. Balzarini, J., M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. 1992. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by a novel HIV-1-specific nucleoside analogue [2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 267:11831-11838.
4. Balzarini, J., M. Stevens, G. Andrei, R. Snoeck, R. Strunk, J. B. Pierce, J. A. Lacadie, E. De Clercq, and C. Pannecouque. 2002. Pyridine oxide derivatives: structure-activity relationship for inhibition of human immunodeficiency virus and cytomegalovirus replication in cell culture. Helv. Chim. Acta 85:2961-2974.
5. Barré-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 220:868-871.
6. Daelemans, D., A.-M. Vandamme, and E. De Clercq. 1999. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir. Chem. Chemother. 10:1-14.
7. Daelemans, D., E. De Clercq, and A.-M. Vandamme. 2001. A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. J. Virol. Methods 96:183-188.
8. De Clercq, E. 2001. New developments in anti-HIV chemotherapy. Pure Appl. Chem. 73:55-66.
9. De Clercq, E. 2002. New anti-HIV agents and targets. Med. Res. Rev. 22:531-565.
10. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promotor. Annu. Rev. Biochem. 63:717-743.
11. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
12. Kingsman, S., and A. J. Kingsman. 1996. The regulation of human immunodeficiency virus type-1 gene expression. Eur. J. Biochem. 240:491-507.
13. Okamoto, H., T. Cujec, M. Okamoto, B. M. Perlin, M. Baba, and T. Okamoto. 2000. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272:402-408.
14. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
15. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
16. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
17. Rey, M.-A., B. Kurst, A. G. Laurent, D. Guétard, L. Montagnier, and A. G. Hovanessian. 1989. Characterization of an HIV-2-related virus with a smaller sized extra-cellular envelope glycoprotein. Virology 173:258-267.
18. Stevens M., C. Pannecouque, E. De Clercq, and J. Balzarini. 2003. Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. Antimicrob. Agents Chemother. 47:2951-2957.
19. Vandamme A.-M., K. Van Vaerenbergh, and E. De Clercq. 1998. Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 9:187-203.